Information Provided By: 
Fly News Breaks for February 12, 2019
NKTR
Feb 12, 2019 | 06:19 EDT
Piper Jaffray analyst Tyler Van Buren believes the 48% overall response rate reported last night by Nektar Therapeutics in bladder cancer "provide positive read-through for an accelerated, response rate approval strategy." The ongoing Phase III trial in cis-ineligible PDL1-neg bladder patients, which is set to report initial data by mid-2020, will likely be the first pivotal trial to readout, Van Buren tells investors in a research note. He keeps an Overweight rating on Nektar shares with a $125 price target.
News For NKTR From the Last 2 Days
There are no results for your query NKTR
